Does Neoadjuvant Hormonal Therapy Improve Urinary Function When Given to Men With Large Prostates Undergoing Prostate Brachytherapy?
- 1 February 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 183 (2) , 634-640
- https://doi.org/10.1016/j.juro.2009.09.084
Abstract
We evaluated the effect of neoadjuvant hormonal therapy on urinary function in men with a prostate volume of 50 cc or greater undergoing prostate brachytherapy. A total of 395 men with 50 cc or greater glands were treated with 3 months of neoadjuvant hormonal therapy (204) or implantation alone (191). Urinary function was assessed by the International Prostate Symptom Score, the urinary retention incidence and subsequent transurethral prostate resection. Median patient age was 67 years and median followup was 6 years. Mean prostate volume in neoadjuvant hormonal therapy cases was 72.9 cc, which decreased to 54.3 cc after 3 months (p <0.001). Mean prostate volume in cases without hormonal therapy was 60.6 cc (p <0.001). Urinary retention occurred in 16 of 191 men (8.4%) without vs 25 of 204 (12.3%) with hormonal therapy (p = 0.207). The median duration of urinary retention was 42 days (range 2 to 243). There were no significant associations of urinary retention with prostate size, prostate or urethral dose, or pre-implantation International Prostate Symptom Score. Of patients without hormonal therapy retention occurred in 3 of 12 (25%) with a pre-implantation International Prostate Symptom Score of 15 or greater and in 13 of 168 (7.7%) with a score of less than 15 (OR 4.0, 95% CI 1-16, p = 0.04). In contrast, there was no difference in the retention rate in patients with hormonal therapy with an initial score of 15 or greater vs less than 15 (2 of 25 or 8% vs 11 of 102 or 10.8%, p = 0.614). Transurethral prostate resection was done in 11 of 191 men (5.8%) without vs 12 of 204 (5.9%) with hormonal therapy (p = 0.958). There was no difference in biochemical failure in the 2 groups. Neoadjuvant hormonal therapy has its greatest benefit in patients receiving brachytherapy who have a large prostate and an International Prostate Symptom Score of 15 or greater.Keywords
This publication has 26 references indexed in Scilit:
- 12-YEAR OUTCOMES FOLLOWING PERMANENT PROSTATE BRACHYTHERAPY IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCERJournal of Urology, 2005
- Radiotherapy for prostate cancer: Brachytherapy aloneUrology, 2004
- Combined modality treatment in the management of high-risk prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 2004
- The effect of hormonal manipulation on urinary function following permanent prostate brachytherapyBrachytherapy, 2004
- Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant qualityInternational Journal of Radiation Oncology*Biology*Physics, 2003
- Prostate Cancer With Large Glands Treated With 3-Dimensional Computerized Tomography Guided Pararectal Brachytherapy: Up to 8 Years of FollowupJournal of Urology, 2003
- Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantationInternational Journal of Radiation Oncology*Biology*Physics, 2002
- 10-year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapyInternational Journal of Radiation Oncology*Biology*Physics, 2001
- Prostate brachytherapy in patients with prostate volumes ≥ 50 cm3: dosimetic analysis of implant qualityInternational Journal of Radiation Oncology*Biology*Physics, 2000
- American brachytherapy society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 1999